Review of angiogenesis in hepatocellular carcinoma

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 1-9

  Muto, Jun ^a   Shirabe, Ken ^a   Sugimachi, Keishi ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

Author keywords

Angiogenesis; Arteriogenesis; Hepatocellular carcinoma

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BRIVANIB; ERLOTINIB; EVEROLIMUS; LINIFANIB; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TIE 1 RECEPTOR; TIVANTINIB; VASCULOTROPIN;

ANGIOGENESIS; DRUG MECHANISM; HUMAN; HYPOXIA; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION;

EID: 84921023438     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12310     Document Type: Review

References (102)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008; 75 (Suppl 1): 13-16.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
5. Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol 2010; 17: 1247-1256.
6. Matsui O, Kobayashi S, Sanada J etal. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011; 36: 264-272.
7. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77.
8. Choi BI. The current status of imaging diagnosis of hepatocellular carcinoma. Liver Transpl 2004; 10: S20-25.
9. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8: 292-301.
10. Chen WX, Min PQ, Song B, Xiao BL, Liu Y, Ge YH. Single-level dynamic spiral CT of hepatocellular carcinoma: correlation between imaging features and density of tumor microvessels. World J Gastroenterol 2004; 10: 67-72.
11. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography - radiologic-pathologic correlation. Radiology 2009; 252: 605-614.
12. Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995; 22: 101-105.
13. Sakon M, Ogawa H, Fujita M, Nagano H. Hepatic resection for hepatocellular carcinoma based on tumor hemodynamics. Hepatol Res 2013; 43: 155-164.
14. Sonoda T, Shirabe K, Takenaka K, Kanematsu T, Yasumori K, Sugimachi K. Angiographically undetected small hepatocellular carcinoma: clinicopathological characteristics, follow-up and treatment. Hepatology 1989; 10: 1003-1007.
15. Tanigawa N, Lu C, Mitsui T, Miura S. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 1997; 26: 1216-1223.
16. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127: S218-224.
17. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006; 10: 45-55.
18. Fujita N, Aishima S, Iguchi T etal. Down-regulation of artery in moderately differentiated hepatocellular carcinoma related to tumor development. Hum Pathol 2010; 41: 838-847.
19. Kim HC, Kim TK, Sung KB etal. CT during hepatic arteriography and portography: an illustrative review. Radiographics 2002; 22: 1041-1051.
20. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 2000; 31: 255-260.
21. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012; 55: 622-633.
22. Yang ZF, Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec 2008; 291: 721-734.
23. Fukumura D, Yuan F, Monsky WL, Chen Y, Jain RK. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 1997; 151: 679-688.
24. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1178-1182.
25. Wada H, Nagano H, Yamamoto H etal. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 2006; 26: 414-423.
26. Kim WY, Safran M, Buckley MR etal. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J 2006; 25: 4650-4662.
27. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004; 5: 437-448.
28. Zeng W, Gouw AS, van den Heuvel MC etal. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology 2008; 48: 1517-1527.
29. Yoshiji H, Kuriyama S, Noguchi R etal. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 2005; 54: 1768-1775.
30. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001; 20: 319-325.
31. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
32. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864-880.
33. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
34. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25-35.
35. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19: 5598-5605.
36. LeCouter J, Moritz DR, Li B etal. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299: 890-893.
37. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010; 140: 268-279.
38. Yang JC, Teng CF, Wu HC etal. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009; 49: 1962-1971.
39. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904-1913.
40. Strizzi L, Catalano A, Vianale G etal. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468-475.
41. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001; 61: 6020-6024.
42. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
43. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380.
44. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534.
45. Amarapurkar AD, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. Ann Hepatol 2007; 6: 170-173.
46. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int 2011; 31: 146-162.
47. Salcedo X, Medina J, Sanz-Cameno P etal. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42: 696-701.
48. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009; 115: 4895-4906.
49. Kaseb AO, Morris JS, Hassan MM etal. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011; 29: 3892-3899.
50. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-2300.
51. Jinno K, Tanimizu M, Hyodo I etal. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998; 33: 376-382.
52. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 1061-1065.
53. Zhao J, Hu J, Cai J, Yang X, Yang Z. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Chin Med J 2003; 116: 772-776.
54. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63: 3121-3126.
55. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10: 2878-2882.
56. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 1354-1360.
57. Jeng KS, Sheen IS, Wang YC etal. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol 2004; 10: 643-648.
58. Cui J, Dong BW, Liang P, Yu XL, Yu DJ. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol 2004; 10: 1533-1536.
59. Claudio PP, Russo G, Kumar CA etal. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance. Clin Cancer Res 2004; 10: 3509-3517.
60. Kanematsu M, Osada S, Amaoka N etal. Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with angiographically assisted CT. AJR Am J Roentgenol 2004; 183: 1585-1593.
61. Xiong ZP, Yang SR, Liang ZY etal. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004; 3: 386-390.
62. Sheen IS, Jeng KS, Shih SC etal. Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11: 187-192.
63. Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 2005; 11: 1705-1708.
64. Yao DF, Wu XH, Zhu Y etal. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 220-226.
65. Deli G, Jin CH, Mu R etal. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005; 11: 960-963.
66. Guo RP, Zhong C, Shi M etal. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132: 547-555.
67. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007; 14: 1835-1845.
68. Amaoka N, Osada S, Kanematsu M etal. Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression. J Gastroenterol Hepatol 2007; 22: 2202-2207.
69. Kanda M, Nomoto S, Nishikawa Y etal. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 2008; 98: 190-196.
70. Wang ZL, Liang P, Dong BW, Yu XL, Yu de J. Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg 2008; 12: 327-337.
71. Tseng PL, Tai MH, Huang CC etal. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol 2008; 98: 349-357.
72. Siegel AB, Cohen EI, Ocean A etal. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998.
73. Mitsuhashi N, Shimizu H, Ohtsuka M etal. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-1113.
74. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73: 2943-2948.
75. Terme M, Pernot S, Marcheteau E etal. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73: 539-549.
76. Gabrilovich DI, Chen HL, Girgis KR etal. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
77. Huang Y, Chen X, Dikov MM etal. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110: 624-631.
78. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-177.
79. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585.
80. Fiedler U, Krissl T, Koidl S etal. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 2003; 278: 1721-1727.
81. Davis S, Aldrich TH, Jones PF etal. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-1169.
82. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693.
83. Maisonpierre PC, Suri C, Jones PF etal. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
84. Holash J, Maisonpierre PC, Compton D etal. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
85. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002; 99: 11205-11210.
86. Zagzag D, Hooper A, Friedlander DR etal. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999; 159: 391-400.
87. Zhang L, Yang N, Park JW etal. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63: 3403-3412.
88. Hashizume H, Falcon BL, Kuroda T etal. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70: 2213-2223.
89. Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003; 56: 854-860.
90. Wilhelm SM, Carter C, Tang L etal. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
91. Chang YS, Adnane J, Trail PA etal. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-574.
92. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
93. Villanueva A. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. J Hepatol 2013; 59: 392-395.
94. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-979.
95. Mendel DB, Laird AD, Xin X etal. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
96. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002; 38 (Suppl 5): S3-10.
97. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95: 851-867.
98. Albert DH, Tapang P, Magoc TJ etal. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006; 5: 995-1006.
99. Guo J, Marcotte PA, McCall JO etal. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006; 5: 1007-1013.
100. Bhide RS, Cai ZW, Zhang YZ etal. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-f][1, 2, 4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 49: 2143-2146.
101. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-1426.
102. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013; 10: 34-42.